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Abstract
Background: Obesity in infertile women increases the costs of fertility treatments, reduces their effectiveness and
increases significantly the risks of many complications of pregnancy and for the newborn. Studies suggest that
even a modest loss of 5–10 % of body weight can restore ovulation. However, there are gaps in knowledge
regarding the benefits and cost-effectiveness of a lifestyle modification program targeting obese infertile women
and integrated into the fertility clinics. This study will evaluate clinical outcomes and costs of a transferable
interdisciplinary lifestyle intervention, before and during pregnancy, in obese infertile women. We hypothesize that
the intervention will: 1) improve fertility, efficacy of fertility treatments, and health of mothers and their children;
and 2) reduce the cost per live birth, including costs of fertility treatments and pregnancy outcomes.
Methods/Design: Obese infertile women (age: 18–40 years; BMI ≥30 kg/m2 or ≥27 kg/m2 with polycystic ovary
syndrome) will be randomised to either a lifestyle intervention followed by standard fertility treatments after
6 months if no conception has been achieved (intervention group) or standard fertility treatments only (control
group). The intervention and/or follow-up will last for a maximum of 18 months or up to the end of pregnancy.
Evaluation visits will be planned every 6 months where different outcome measures will be assessed. The primary
outcome will be live-birth rates at 18 months. The secondary outcomes will be sub-divided into four categories:
lifestyle and anthropometric, fertility, pregnancy complications, and neonatal outcomes. Outcomes and costs will be
also compared to similar women seen in three fertility clinics across Canada. Qualitative data will also be collected
from both professionals and obese infertile women.
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Discussion: This study will generate new knowledge about the implementation, impacts and costs of a lifestyle
management program in obese infertile women. This information will be relevant for decision-makers and health
care professionals, and should be generalizable to North American fertility clinics.
Trial registration: ClinicalTrials.gov NCT01483612. Registered 25 November 2011.




Infertility affects approximately 10–15 % of couples [1].
One of the leading causes in women is anovulation
caused by the polycystic ovary syndrome (PCOS) [2, 3],
which affects 6–10 % of women of childbearing age [4].
PCOS accounts for more than 70 % of anovulatory infer-
tility in women [5]. This syndrome is defined by hyper-
androgenism and anovulation/polycystic ovaries [3], and
its etiology is related to elevated insulin resistance and
obesity in genetically predisposed women [6–9]. Accord-
ingly, 50–75 % of women with PCOS are obese in North
America [10]. Obesity increases the risk of PCOS, but it
has also been associated with reduced fertility even in
ovulatory women [11–13]. As of 2008, 44 % of Canadian
women of reproductive age (20 to 44 years) were re-
ported as being overweight (body mass index (BMI) 25.0
to 29.9 kg/m2, 25 %) or obese (BMI ≥30.0 kg/m2, 19 %)
[14]. Also, a survey in Scotland found a significantly
higher proportion of obesity in infertile women [15].
Obesity increases the costs of fertility treatments and
reduces their effectiveness. Indeed, pharmacological in-
duction of ovulation is less effective in obese PCOS
women [16], with the ovulatory dose of clomiphene be-
ing positively correlated with BMI [17]. Obesity delays
time to conception when using intrauterine donor in-
semination [18] and reduces conception following
assisted reproductive technologies (ART) [19], with
higher required doses of gonadotropins [20], lower im-
plantation and pregnancy rates [20–22], and higher mis-
carriage rates [20–23]. In addition to fertility disorders,
obesity increases significantly the risks of many compli-
cations of pregnancy, such as gestational diabetes, pre-
eclampsia, caesarean section, intrauterine death, which
are further increased in morbidly obese women [24–26].
During the postpartum period, overweight mothers are
more likely to have hypertension and thromboembolism,
leading to a higher risk of maternal mortality [27]. Obes-
ity has also been associated with an increased risk of
birth defects, such as ventral wall, neural tube, cardiac
and multiple congenital defects [28]. Pregnancy and de-
livery procedures in obese women are therefore more
costly, mainly because of increased caesarean section
rates, length of hospital stay and admission to neonatal
intensive care [29–31]. It was estimated that the overall
costs of fertility treatments and pregnancy complications
were increased by 44–54 % and 70–100 % in overweight
and obese women, respectively, compared to their nor-
mal weight counterparts [32]. Moreover, offspring from
obese women are more likely to develop obesity, type 2
diabetes (DM2) and cardiovascular diseases in their life-
time, often at a younger age [33]. Studies suggest that
maternal obesity, via a pro-inflammatory milieu, insulin
resistance, or other hormonal factors [33, 34], modify
the in utero environment and might induce fetal epigen-
etic programming [35] which predisposes to the devel-
opment of obesity and DM2 early in life, thus
perpetuating the vicious circle of obesity and its comor-
bidities in subsequent generations.
Obesity management in women seeking fertility
treatment
Collectively these substantive maternal and fetal risks
call for women to lose weight prior to assisted concep-
tion in order to improve their fertility and chance of a
healthy pregnancy [22, 36]. Indeed, it has been shown
that a supervised lifestyle modification program, includ-
ing support in addition to diet and exercise advice, can
reduce weight, increase ovulatory frequency and improve
pregnancy rates [37–39]. Even a modest weight loss of
5–10 % of total body weight can restore ovulation
[40, 41]. The Fertility Fitness Program founded by Dr
Norman in Australia is a 6-month program of weekly
group sessions targeting behavioural changes that include
exercise and diet. Clark et al. [39] found that in over-
weight, infertile, anovulatory women, this program re-
sulted in an average weight loss of 6.3 kg, a restoration of
ovulation in 12 of the 13 subjects and pregnancy in 11
women. In a follow-up study, 67 anovulatory obese
women who completed the program lost an average of
10.2 kg with 90 % of them resuming spontaneous ovula-
tion [38]. Of these participants, 78 % achieved a pregnancy
and 67 % a live birth [38]. Recently, a randomized con-
trolled trial (RCT) was completed in Australia with 171
obese infertile women and demonstrated that the program
induced greater weight loss than the control intervention
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(4.7 vs. 1.3 kg, P < 0.001) and increased pregnancy rates at
18 months from 21 to 61 % (P < 0.001) (Clark et al.,
unpublished).
A study conducted by our group shows that it is
possible for obese women with PCOS to achieve clin-
ically significant and sustained weight loss by follow-
ing simple advice given in a regular clinical care
setting [42]. We retrospectively reviewed weight
changes of young obese PCOS women and found that
43 % of 74 women lost ≥5 % of their initial weight
after 6–12 months of follow-up. Young obese PCOS
women seem to be a responsive population to lifestyle
modification and it is thus expected that an inte-
grated interdisciplinary lifestyle program will be even
more effective in a similarly young population of
obese women who are also highly motivated by their
desire for a healthy baby.
Effective and acceptable lifestyle-modification strat-
egies have the highest potential to result in a reduction
in the socioeconomic burden of the obese pregnant
woman. Indeed, the American Society for Reproductive
Medicine [43], the American Dietetic Association [44],
the American Society for Nutrition [44], the European
Society of Human Reproduction and Embryology [45]
and the British Fertility Society [46] have recommended
that overweight/obese women should be provided with
assistance to lose weight prior to conception and main-
tain a healthy lifestyle to prevent excess weight gain dur-
ing pregnancy. The “Canadian clinical practice
guidelines on the management and prevention of obesity
in adults and children” emphasizes the importance of
the multidisciplinary health care team for effective
weight management [47]. After assessment of co-
morbidities and readiness to change, a lifestyle modifica-
tion program is proposed as the first step with an object-
ive of 5–10 % weight loss. Our group implemented an
interdisciplinary approach to obesity management at the
Centre hospitalier universitaire de Sherbrooke (CHUS)
since 2001. We have demonstrated in the general obese
population that this low-cost approach leads to clinically
significant weight loss [48–50]. However, access to our
specialized programs is limited by a long waiting list
with prohibitive delays for obese women seeking fertility
treatment. They require rapid access to a lifestyle pro-
gram tailored to their specific needs. At this time, there
is no integrated lifestyle modification program targeting
this specific population in the North American public
health care systems. There are gaps in knowledge re-
garding the benefits and cost-effectiveness of such inter-
vention in the North American context that our study
will address. The development of a new initiative aiming
at increasing efficiency and reducing the costs of fertility
treatments, while improving the health of mothers and
their offspring is needed.
Hypothesis
We hypothesize that an interdisciplinary lifestyle inter-
vention taking place before and during pregnancy in
obese infertile women will: 1) improve fertility, efficacy
of fertility treatments, and health of mothers and their
children; and 2) reduce the cost per live birth and costs
of fertility treatments and rates of adverse pregnancy
outcomes. We further propose that our research pro-
gram will 3) result in generalizable and transferable new
knowledge useful for decision-makers of the health care
system.
Study objectives
This study protocol aims to design, implement and
evaluate a transferable cost-effective program for lifestyle
management of obesity in infertile women integrated
into the fertility clinics. To achieve this goal, the pro-
posed project will focus on four specific objectives:
1) To design and implement an interdisciplinary
program for lifestyle management of obese women,
or overweight women with PCOS, who seek fertility
treatment at the CHUS, a fertility clinic with
provincial coverage of fertility treatments and
satellite access to in vitro fertilization (IVF);
2) To evaluate lifestyle benefits of this program and
assess its impact on fertility, pregnancy
complications and neonatal outcomes, as compared
to a randomly assigned control group and to similar
women seen in three fertility clinics across Canada
with and without public coverage of fertility
treatments;
3) To assess cost per live birth, and other measures of
cost-effectiveness, of this program compared to the
control group and three fertility clinics across
Canada with and without public coverage of fertility
treatments; and
4) To effectively transfer knowledge obtained through
these activities to relevant stakeholders in the health
care and public health sectors, including policy-
makers, decision-makers, health care professionals
and patients.
Methods/Design
Study design and setting
The proposed study relies on a participatory research
approach which will combine quantitative and qualita-
tive assessments. The impacts of the lifestyle program
that will be developed will be assessed using a random-
ized controlled trial in one academic center. The study
was registered to ClinicalTrials.gov (NCT01483612).
The RCT will be conducted at the CHUS fertility
clinic, a fertility clinic with satellite access to IVF. The
clinic offers care to patients with a range of reproductive
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problems including infertility, recurrent pregnancy loss,
anovulation, PCOS, hyperprolactinemia, endometriosis,
etc. The clinic has a successful ovulation induction and
superovulation program including intrauterine insemin-
ation and access to donor sperm. Since 2011, it offers an
IVF program in collaboration with Procrea Cliniques ini-
tially, and subsequently with the assisted reproduction
center of the CHU Ste-Justine, where only the egg re-
trievals and embryo transfers are performed (evaluation
of patients, protocol prescription, monitoring and deci-
sion making before and during cycles is done in Sher-
brooke). Clinical outcomes and costs will be compared
to a randomly assigned control group and to similar
women seen in three fertility clinics across Canada not
offering specific weight loss interdisciplinary lifestyle
program: 1) an intra-provincial clinic (Procrea Cliniques,
Montreal) with public coverage of fertility treatments; 2)
2 extra-provincial clinics (Centre for Fertility and Re-
productive Health and IVF Unit at Mount Sinai Hos-
pital, Toronto; and Fertility Clinic of Royal Alexandra
Hospital, Edmonton) without public coverage of fertil-
ity treatments. These centers offer the full range of
ART on site.
Study participants
Study participants will be recruited among all women
consulting at the CHUS fertility clinic. The staff will as-
sist the research team in identifying potential partici-
pants. To be included in the study, women must fulfill
the following inclusion criteria: 1) infertility; 2) aged be-
tween 18 and 40 years; and 3) obesity (BMI ≥30 kg/m2)
or overweight if PCOS (BMI ≥27 kg/m2). Women will
be excluded if they had bariatric surgery or plan for it
and/or if natural conception is impossible or highly un-
likely (tubal factor, severe male factor infertility, etc.). In-
fertility will be defined as: 1) failure to achieve a clinical
pregnancy after 12 months or more of regular unpro-
tected sexual intercourse in women who are under
35 years with regular menstrual cycles; 2) women who
do not have regular menstrual cycles, or are older than
35 years and have not conceived during a 6-month trial
period; or 3) women with a known cause of infertility.
Eligible patients will be referred to the research coordin-
ator to obtain their individual informed consent prior to
baseline data collection.
Ethical considerations
The proposed research was reviewed and approved by
the Institutional Research Ethics Review Boards of the
CHUS and other fertility clinics. Both research partici-
pants and health professionals will be duly informed and
consent will be obtained in writing prior to evaluations
or focus groups. This includes the 20 patients who will
be randomly selected from other Canadian fertility
clinics to be evaluated at the end of the study using the
same questionnaires and focus group as patients at the
CHUS. The main ethical consideration of the proposed
research is confidentiality issues that will be minimized.
All data will be coded, archived for at least 5 years and
then destroyed.
Randomisation
An independent statistician will use computerised ran-
dom number generation to allocate each participant to
the intervention or control group. Randomisation will be
stratified according to the PCOS or non-PCOS status,
based on clinical diagnosis in the patient’s record. Se-
quences will be generated using permuted block ran-
domisation, with block sizes of two, four or six entries.
The allocation sequence will be concealed in corre-
sponding sequentially numbered opaque envelopes.
After a participant has completed baseline assessments,
the research coordinator will open the envelope to reveal
the group allocation to the participant. Participants will
be informed of their group assignment at that time.
Intervention
Control arm
Participants assigned to the control group will receive
standard fertility treatments, which will be initiated as
soon as clinically indicated. Standard fertility treatments
may include lifestyle counselling by the obstetrician-
gynecologist certified in gynecologic reproductive endo-
crinology and infertility (GREI), reproductive endocrin-
ologist or fertility specialist in charge of the care of the
patient.
Intervention arm
Participants allocated to the intervention group will be
invited to participate in the interdisciplinary lifestyle
intervention and will have to delay other fertility treat-
ments for six months. After 6 months of lifestyle inter-
vention alone, women who are not pregnant will begin
pharmacologic fertility treatments, as indicated, in con-
junction with the lifestyle intervention that will continue
to be offered. The aim of the intervention will be to im-
plement progressive and sustainable lifestyle changes in
order to reach a modest weight loss. Women will be in-
vited to individually meet with a dietitian and a kinesi-
ologist (20–30 min each) at 0, 3, 6 weeks and then every
6 weeks over a period of 18 months or until the end of
pregnancy. A follow-up phone call/email will also take
place once between each meeting for additional support.
The dietitian will use 3-day food records to evaluate the
women’s food intake throughout the program. To help
improve patient’s diet, Canada’s Food Guide and the
“Healthy Plate” [51] will be the main tools use for nutri-
tional counselling. The kinesiologist will be responsible
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for taking anthropometric measures and vital signs and
for coaching women to increase their physical activity
level. A pedometer will be offered to assist the patient.
Patients will be guided by the dietitian and the kinesiolo-
gist to formulate S.M.A.R.T goals (specific, measurable,
attainable, realistic, and timely) at each meeting. The
members of our interdisciplinary team will be trained in
motivational interviewing. This training can positively
affect the attitude to behaviour change in obese infertile
women [52].
Besides individual intervention, women will benefit
from a series of 12 educational group sessions (45-mi-
nute interactive small group workshops and 45-minute
physical activity) covering various topics relevant to
obesity management and fertility (Table 1). The work-
shops will be conducted by either the dietitian or psych-
ologist and the demonstration of physical activity will be
performed by the kinesiologist. These group sessions will
take place weekly. When a pregnancy is confirmed, the
woman will be met to set new objectives specific to her
pregnancy, including an optimal gestational weight gain
based on Institute of Medicine guidelines [53]. Partners
will be invited to join individual meetings and strongly
encouraged to assist all group sessions. To our know-
ledge, this is the first study assessing a lifestyle interven-
tion in obese infertile women that is continued during
fertility treatments and pregnancy.
Committees overseeing the study
To facilitate the inclusion of all relevant stakeholders,
four committees will be involved throughout program
development and implementation, as well as the evalu-
ation process.
Steering committee
This committee will bring together relevant medical ex-
perts of various disciplines (endocrinology, obesity,
GREI) and health care decision-makers from the CHUS.
It will be responsible for supervising the development of
the intervention, the planning of the evaluation, and the
monitoring of the intervention implementation at the
CHUS. It will overlook the work of all subcommittees
and the course of implementation, with difficulties and
proposed solutions, and will decide the directions for
the intervention and the research plan. Steering commit-
tee meetings will occur regularly, as needed, and will
also serve as knowledge transfer activities where
decision-makers and knowledge users will be informed
about the implementation and the results of the
research.
Advisory committee
This committee will gather experts and decision-makers,
who actively collaborate to this research project but are
external to our institution, especially colleagues at the
three fertility clinics of comparison. This committee will
advise the research team on design of the intervention
and planning of the evaluation, including evaluations on
their sites. The Advisory committee will meet as needed
and will be actively involved in revising documents and
through informal communications. Post-intervention
meetings will also serve as knowledge transfer activities.
Intervention sub-committee
This sub-committee will be in charge of developing the
intervention in all its details and to follow-up closely on
its implementation. This sub-committee will meet every
Table 1 Topics of the interactive workshops and physical activities of the Obesity-Fertility group sessions program
Sessions Interactive workshops Physical activities
1 Nutrition: Canada’s Food Guide Walking
2 Psychology: Couple Communication Aquafitness
3 Nutrition: Energy Density of Foods: Healthy
Substitutions for Weight Loss
Step Aerobics
4 Psychology: Stages of Behaviour Change and Motivation Strength Training at Home
5 Nutrition: Environmental Factors – Impact on Food Intake Interval Walking
6 Psychology: Sleep and Relaxation Yoga
7 Nutrition: Managing Hunger and Satiety Exercising While Watching TV
8 Psychology: Eating Disorders vs. Compulsive Overeating
and Actions Strategies
Aquafitness
9 Nutrition: Meal Planning Tips/ Alcohol and Smoking Walking in Combination with Cardio and Muscular
Endurance Exercises
10 Psychology: Self-Esteem and Body Image Strength Training with Exercise Ball and Resistance Band
11 Nutrition: Understanding a Food Label Circuit Training
12 Psychology: Behaviour Self-Assessment Aerobic Dance Workout
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month before the project begins and then as needed
until the end of the intervention.
Evaluation sub-committee
This sub-committee will develop all the evaluation tools
and will plan the qualitative evaluations. It will be par-
ticularly active before the start of the intervention and at
the end of the intervention for the qualitative evalua-
tions on all sites.
Development & implementation of the lifestyle program
for obese infertile women (Objective 1)
The Intervention sub-committee will be directly in
charge of defining the intervention and planning the
implementation. A complete review of the relevant lit-
erature will be performed initially and made available
to all other committee members. The implementation
of the program will be closely monitored by this sub-
committee with evaluation of required human, mater-
ial and other resources; barriers that will be encoun-
tered; potential solutions that will be applied; and
discussion of difficult cases managed in the program.
In addition, a specific qualitative evaluation of the
program implementation will take place at the end of
the intervention and will be planned by the Evalu-
ation sub-committee. All women included in the
CHUS RCT will be evaluated by questionnaires and a
sub-group of 20 of these patients will be selected to
participate in focus groups. In order to compare
health professionals’ and patients’ satisfaction, percep-
tions and impact of the program on their life to those
during usual care in Canada, we recruited three Can-
adian fertility clinics with different characteristics. In
these clinics, 20 patients randomly selected will be
evaluated at the end of the study using the same
questionnaires and focus group methods. In all four
centers, health care providers involved in the fertility
clinic and/or the program will also be evaluated by
questionnaires and focus groups.
This objective will be under the supervision of our
Steering committee and Advisory committee.
Decision-makers from Quebec and Canada who sit on
these committees will ensure that our program meets
their objectives and is acceptable in terms of required re-
sources and costs. Furthermore, we will validate our pro-
gram design and evaluation plan with worldwide key
experts as well as Canadian obesity experts contacted
through the Canadian Obesity Network (CON). We will
benefit from the experience of experts involved in the
implementation and evaluation of similar programs: the
Fertility Fitness program in Australia and the Lausanne
Obesity-Fertility clinic in Switzerland.
Evaluation of clinical outcomes of the lifestyle program
for obese infertile women (Objective 2)
The primary outcome will be live-birth rates at
18 months. Secondary outcomes will be sub-divided
into four categories of clinical outcomes:
1) Lifestyle and anthropometric outcomes: evolution of
anthropometric measures, changes in lifestyle habits
(diet, exercise, sleep, alcohol, and tobacco), physical
fitness level, daily energy expenditure from physical
activities, time spent in various physical activity
intensities, step count, evolution of readiness for
change, quality of life.
2) Fertility outcomes: pregnancy rate (biochemical
pregnancy confirmed by a positive beta-human
chorionic gonadotropin (β-hCG) level in the serum),
spontaneous abortions, multiple pregnancies, spon-
taneous vs. ART-induced pregnancy, doses of fertility
medications, number of treatment or IVF cycles.
3) Pregnancy adverse outcomes: gestational diabetes,
hypertension, pre-eclampsia, thromboembolism, cae-
sarean section.
4) Neonatal outcomes: birth weight, hypoglycemic
episodes, Apgar score, jaundice, admission to
neonatal intensive care, congenital defects,
intrauterine death.
The results obtained at the CHUS will also be com-
pared to those of women with the same criteria who will
be seen in three fertility clinics across Canada. At the
CHUS, primary and secondary outcomes will be deter-
mined using patients’ assessments, questionnaires and
review of patients’ records. At the comparative clinics,
charts of patients seen during the same time period will
be retrospectively reviewed, and administrative data will
be gathered.
Cost-effectiveness assessment of the lifestyle program for
obese infertile women (Objective 3)
Data collected for this objective will trace the operating
costs (human and material resources) for each of the pa-
tients in the study based on two viewpoints: 1) the costs
for the public health system; and 2) the costs for the pa-
tients. The two viewpoints will translate into two models
of costs for all analyses. The key variable of interest is
the total cost per live birth. This variable will be mea-
sured in two ways: 1) the total cost per infant alive for
all women, which considers costs of unsuccessful inter-
ventions; and 2) the total cost per infant alive only for
the women who had a live birth. Costs will include:
Costs of the lifestyle program
Health care system viewpoint – Costs for health care
providers and staff (medical visits with corresponding
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billing, number of hours worked by health professionals
and administrative staff ), interdisciplinary meetings with
case discussion, meetings related to the operation of the
program, medical testing, consumables. Patients’ view-
point – Costs for transportation, parking, loss of salary
(patient & life partner), daycare.
Costs of fertility treatments
Health care system viewpoint – Costs for health care
providers and staff (idem), drugs, medical testing, con-
sumables, and billing of ART-related investigations or
treatments to the public system if applicable. Patients’
viewpoint – Costs for transportation, parking, loss of sal-
ary, daycare, drugs not covered, and billing of ART-
related investigations or treatments to the patient if
applicable.
Costs of adverse events or complications
Health care system viewpoint – Costs of hospitalization
or drugs for adverse events related to the lifestyle pro-
gram, fertility treatments, pregnancy or neonatal care.
Patients’ viewpoint – Costs for transportation, parking,
loss of salary, daycare, drugs not covered, incurred by
the patients due to these adverse events or
complications.
Data collection will be performed through patients’
charts review, administrative data, questionnaires and in-
terviews with health care providers and staff of fertility
clinics for the description of care procedures, as well as
questionnaires to patients. At the CHUS fertility clinic,
costs will be obtained prospectively and all patients will
answer a specific questionnaire; but for the three fertility
clinics of comparison, patients’ charts will be retrospect-
ively reviewed. However, as mentioned, a sample of 20
patients will be selected for focus groups: these patients
will also answer the same cost questionnaire. Thus, the
exact costs from the patients’ viewpoint of the different
events will be determined based on these 20 patients
and then be extrapolated to the other patients. Depart-
ments or directorates of service (billing services at the
CHUS, pharmacies, Human Resources, Department of
Nursing) will be consulted to match each event to its
monetary cost. Where possible, we will use the overhead
costs, provided by the administrative services, for a par-
ticular treatment and/or complication. When this is not
possible, we will conduct interviews with relevant pro-
fessionals to track the various human resources and ma-
terials that were involved.
Since provincial and state pricings for the different
outcomes are different, we will only consider a single
reference price for each outcome, i.e. pricing in the Que-
bec health system. In order not to incur double counting
in calculating the cost of primary outcome, we will make
sure to check the reason for the expense and we will
record every cost only once for the primary outcome.
Regarding the joint use of equipment or spaces, the cost
used will be the unit cost of depreciation for each use or
visit. To the extent that the cost measure will be done
over a period exceeding one year, we will use a discount
rate. The reference discount rate will be 5 % per year.
To test the robustness of our results, we also do a sensi-
tivity analysis with rates of 3 and 8 %.
Assessment of quality-adjusted life years (QALYs) and
cost-effectiveness of the intervention will be performed
using the Short Form-6D (SF-6D). SF-6D is a generic
preference-based measure of health derived from the
SF-36 Health Survey for use in economic evaluation
[54]. It is composed of six dimensions of health: physical
functioning, role limitations, social functioning, pain,
mental health and vitality. Each dimension has between
4 and 6 levels. The SF-6D defines 18,000 different pos-
sible health states, and has a range from 0.3 (worst
health state) to 1.0 (best health state) in model 10 [54].
Variables and research tools
Specific research tools for each objective are summa-
rized in Table 2, which includes corresponding variables
as well as the sources that will be used to obtain re-
quired data and the time of data collection.
Health professionals’ perceptions and satisfaction
(Objective 1)
Health professionals’ attitudes, perceptions, self-efficacy
toward obesity management, and other characteristics
(age, experience in obesity management) will be evalu-
ated with a questionnaire that we have developed and
used in previous studies [55]. Self-efficacy is defined as
the set of beliefs about one’s capabilities to perform at a
designated level. It is particularly important in the con-
text of the implementation of a new program since it
may be influenced by the practice environment [56]. For
health professionals to engage in weight management
with their patients, they must not only accept this as
part of their role but also feel that they are competent to
accomplish the task. Negative attitudes toward obese in-
dividuals and perceptions to the effect that available
treatments are ineffective can prevent the engagement of
health professionals in weight management. There is
also a positive correlation between the feeling of compe-
tency and the degree of engagement regarding various
aspects of obesity management and improved attitude
towards obese individuals [57, 58]. A separate question-
naire will gather detailed information on strengths of the
program, difficulties and areas of possible improvement.
A qualitative in-depth analysis of key stakeholder per-
ceptions of the program and fertility clinics will be
performed using semi-structured interviews (MDs,
nurses, dietitians, kinesiologists, psychologists, clinic
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Table 2 Summary of methodology and approach
Variables Sources Time of data collection
CHUS-RCT Comparison
fertility clinics
1. Development and implementation of the interdisciplinary lifestyle intervention
Health professionals’ perceptions
and satisfaction toward obesity
and fertility management
Questionnaire At the end of the study Retrospectively
Focus groups
Patients’ perceptions and satisfaction
toward weight management and
fertility care
Questionnaire At 18 months or 24–28
weeks pregnant
At the end of
the study
Focus groups
2. Evaluation of lifestyle benefits and impact on fertility, pregnancy complications and neonatal outcomes
Live-birth rate Review of patient medical record Throughout the study Retrospectively
Lifestyle and anthropometric
outcomesa
Baseline, 6 months, 12
months, and 18 months.
Among women who become
pregnant: beginning of the
pregnancy and 24–28 weeks
pregnant.
N/A
Anthropometric measures Standard calibrated scale and
standing electric bioimpedance
Vital signs Automatic blood pressure monitor
Metabolic markers related to
insulin secretion, androgen,
lipid profile and OGTT
Blood sample
Lifestyle habits (diet, exercise,
sleep, alcohol, and tobacco)
Questionnaire adapted from the
one used by Statistics Canada for
the latest Canadian Health Survey
Physical fitness level Six-minute walk test
Daily energy expenditure
from physical activities, time
spent in various physical activity
intensities and step count
Tri-axial accelerometer
Readiness for change Questionnaire (WLRT [75])
Quality of life Questionnaire (FertiQoL [76])
Fertility outcomes Throughout the study Retrospectively
Pregnancy rate Positive β-hCG level in the serum
Others Review of patient medical record
Pregnancy adverse outcomes Review of patient medical record Throughout the study Retrospectively
Neonatal outcomes Review of patient medical record Throughout the study Retrospectively
3. Evaluation of cost per live birth/cost-effectiveness of the interdisciplinary lifestyle intervention
Costs of the interdisciplinary
lifestyle interventiona
Questionnaires Throughout the intervention N/A
Administrative data












Table 2 Summary of methodology and approach (Continued)
Questionnaires
Administrative data
Costs of adverse events or
complications




Scientific meeting presentations ASRM, CSEM, ENDO and other
annual meetings
Throughout the study
Publication in scientific journals Human reproduction, Fertility
and sterility, Journal of clinical







Diffusion to stakeholders Conduit, letters, e-mails Throughout the study
Executive summary At the end of the study
ART Assisted reproductive technologies, β-hCG Beta-human chorionic gonadotropin, IVF In Vitro Fertilization, ASRM American society for reproductive medicine, CSEM Canadian society of endocrinology and metabolism,
ENDO Endocrine society, FertiQoL Fertility quality of life tool, OGTT Oral glucose tolerance test, WLRT Weight loss readiness tool












administrative personnel and directors), as we have pre-
viously done [59, 60]. This will increase our understand-
ing of their personal experience, inter-professional
collaboration and satisfaction with the program, and fur-
ther identify and detail strengths and areas for potential
improvement. This will also permit a better understand-
ing of the change process.
Patients’ perceptions and satisfaction (Objective 1)
Patient expectations and perceptions of their personal
experience regarding weight management, fertility
care and pregnancy follow-up, as well as their satis-
faction regarding management by their health profes-
sionals will be evaluated with questionnaires based on
experience from previous studies. A qualitative in-
depth analysis of patients’ perceptions of the program
and medical care will also enhance our understanding
of their personal experience with the program. After
the completion of the quantitative evaluation of im-
pact of the program on patients, a theoretical sample
based on the technique of critical incidents will be
used to create a sub-sample of the whole group.
Twenty patients will be recruited in each of the 4
participating clinics (80 patients). To be recruited
those patients will have to show certain characteristics
(different levels of satisfaction with their care (at
CHUS, based on questionnaires), different fertility or
pregnancy outcomes, loss or gain of weight during
follow-up, etc.). The patients will be participating in a
taped-recorded semi-structured qualitative interview
to assess their perceptions of impact of their partici-
pation into the program (continuity of care, percep-
tions of changes, contribution to change, quality of
life, perspectives of future changes, explanation of
level of satisfaction with the program). An interview
guide with open-ended questions adapted from the
principal variables of the study, the Diabetic Em-
powerment Scale (DES) [59], and the Impact of
Weight on Quality of Life (IWQOL-lite) questionnaire
[61] will be used as done in previous studies from
members of our group [49, 62].
Evaluation of anthropometric and lifestyle benefits and
impact on fertility, pregnancy and neonatal outcomes
(CHUS only) (Objective 2)
Evaluations of anthropometric measures and lifestyle
habits will take place at baseline, prior to randomisation,
and then every 6 months for 18 months. Among women
who become pregnant, data will be collected, at the be-
ginning of the pregnancy and at 24–28 weeks. If a
woman becomes pregnant within a month of a standard
evaluation visit, this visit will be considered as the first
pregnancy visit. If a miscarriage occurs, the original
follow-up will continue until 18 months or the end of
another pregnancy. An overview of the study design and
data collection is provided in Fig. 1.
Anthropometric measures and vital signs: Weight will
be measured by a standard calibrated scale and height
will be measured with a stadiometer. In non-pregnant
women, waist circumference will be measured with a
measuring tape, as recommended [47, 63]. Fat mass and
percent body fat will be measured by standing electric
bioimpedance, which was shown to be reliable compared
to underwater weighing and supine tetrapolar bioimpe-
dance [64, 65]. Blood pressure and pulse rate will be
measured after five minutes of rest, in the sitting pos-
ition. The average of two measurements will be used for
analysis.
Blood sample: Different metabolic markers related to
insulin secretion, androgen and lipid profile will be mea-
sured fasting: apolipoprotein B (ApoB), total cholesterol,
triglycerides, high-density lipoprotein cholesterol (HDL),
low-density lipoprotein cholesterol (LDL), cholesterol ra-
tio, thyroid-stimulating hormone (TSH), prolactin (PRL),
cortisol, adrenocorticotropic hormone (ACTH), β-hCG,
total and free testosterone, Sex hormone-binding
globulin (SHBG), 17-hydroxyprogesterone, dehydro-
epiandrosterone sulfate (DHEAS), androstenedione, C-
peptide, glucose and insulin. A 2-hour oral glucose
tolerance test (OGTT) will be also performed with
blood sample taken every 30 min. Samples will be
stored at each time points for future measurements
of adipokines or other analytes pertinent to the objec-
tives of this study, if funding allows it.
Lifestyle: Physical activity level and eating habits will be
measured using a questionnaire adapted from the one
used by Statistics Canada for the latest Canadian Health
Survey. This questionnaire inquires about the frequency
and duration of active travelling, leisure time, and seden-
tary activities (television watching, video games, com-
puters). We chose this questionnaire since it allows
comparison of the characteristics of our patients to
those of the general Canadian population. Moreover,
women will be asked to wear a tri-axial accelerometer
(GT3X+, Actigraph, Pensacola, FL, USA) on their hip
for seven consecutive days except during sleep and
showering/bathing. The accelerometer will be used to
estimate daily energy expenditure from physical activ-
ities, time spent in various physical activity intensities
and step count. The GT3X+ has been shown to be a
valid and reliable measure of physical activity in free liv-
ing conditions [66].
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Fitness level: The six-minute walk test (6MWT) is a
simple test that has been used to estimate functional
capacity in obese subjects and is also a predictor of mor-
bidity and mortality [67–69]. The 6MWT will be per-
formed according to the protocol recommended by the
American Thoracic Society in a 20-meter hallway
marked every 5 m with coloured tapes on the floor, and
measures the distance that a patient can quickly walk in
a period of 6 min [70]. It has been shown that weight
loss increases fitness level early in the weight loss
process, making this test a very accurate tool to evaluate
the impact of the intervention on obese or overweight
patients’ functional capacity [71–73].
Readiness for change: In the course of previous pro-
spective studies, we have designed a 22-question
weight loss readiness tool (WLRT) questionnaire
based on Prochaska and DiClemente’s Stages of
Change Model [47, 74]. It evaluates the motivational
readiness of patients regarding weight management,
nutrition and physical activity, and could predict response
to an intervention. Our WLRT takes 5–10 min to fill out,
making it a clinically applicable tool. It has been useful to
identify subjects with greater chances of success for life-
style modification in a previous pilot study [75]. Its pre-
dictive value will be assessed in this study, but it will also
serve to explore the mechanisms of potential benefits of
our intervention and for stratified analyses.
Quality of life: The impact of fertility problems and its
treatment on quality of life will be measured using the
fertility quality of life (FertiQoL) tool, a reliable and sen-
sitive questionnaire to evaluate quality of life in individ-
uals with fertility problems [76].
Evaluation of fertility, pregnancy complications and
neonatal outcomes (all sites)
Medical records: Chart review of the mother will be
performed using a standardized evaluation grid, and we
Fig. 1 Summary of design and data collection of the Obesity-Fertility protocol
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will check personal medical and surgical history, medica-
tions, weight, and any particular events at each visit.
This chart review will also identify information about
fertility treatments and pregnancy complications. Infor-
mation about the newborn will be collected via the ob-
stetric file of the mother.
Administrative data and other databases: Data from
the chart review will be cross-validated with administra-
tive data and any databases used in fertility clinics and/
or local hospitals. At the CHUS, all laboratory testing
and all information regarding hospitalisations are
merged together and kept in the “Centre informatisé de
recherche évaluative en services et soins de santé” (CIR-
ESSS) database, which is available for research with ap-
propriate authorizations.
Data analyses and interpretation
For objectives 1–2, all comparisons between randomized
groups at the CHUS will follow both the intent-to-treat
and/or per-protocol principles, and will consider results
at the end of study. For repeated measures, the last-
observation-carried-forward method will be used for
women who drop out or become pregnant (depending
on analyses). Time-to-event analyses will also be per-
formed for fertility outcomes, with censoring for drop
out alone, as well as for anthropometric outcomes, with
censoring for both drop out and occurrence of preg-
nancy. Univariate analyses will compare the change in a
variable in the intervention group with the change in
this variable in the control group, using two-tailed un-
paired t tests (for continuous variables) and chi-square
or Fisher’s exact tests (for categorical variables). Changes
in weight will also be compared for the same follow-up
duration with changes for women seen at the other fer-
tility clinics, using ANOVA tests. For the other variables,
only end-of-study comparisons will be performed be-
tween the two groups in Sherbrooke and the three other
fertility clinics, using ANOVA tests (for continuous vari-
ables) and logistic regressions (for categorical variables).
Bonferroni-corrected p-values will be performed to ad-
just for the multiplicity of comparisons and an α level of
5 % will be considered significant for all analyses. Con-
tinuous variables that are not normally distributed will
be log-transformed in order to ascertain normal distri-
bution. Multivariate analyses will also be used in order
to adjust for baseline differences and for potential con-
founders, and to determine independent predictors of
outcomes. Triangulation will be performed between
quantitative and qualitative data.
Sample size
Our sample size estimation is based upon our primary
outcome (see Objective 2), which is live-birth rates
between randomized groups at the CHUS. Based on the
Fertility Fitness Program, the inclusion of 58 women per
group will provide our study a power of 80 % to identify
a doubling in live-birth rates with our program (25 to
50 %, α = 5 %). Assuming a dropout rate of 10 % (these
women are usually highly motivated), our final estimated
sample size will be 128 women. For other objectives and
outcomes, it would be difficult to assess power because
similar evaluations have not been previously reported.
Knowledge translation and transfer plan (Objective 4)
It is worth mentioning that both our research program
and research design are optimal to allow knowledge
translation (KT) and application throughout the entire
research process. Integrated KT is an important out-
come of this research and will take form of regular
meetings of the Advisory and Steering committees. Be-
cause of the involvement on these committees of repre-
sentatives of Quebec and Ontario Ministries of Health,
fertility clinics and CON, as well as expert clinicians, dif-
fusion of results and exchange of experiences will be
facilitated.
However, research by itself does little to induce change
(except for participants) and thus, results have to be dif-
fused to interested audiences. Our research is relevant to
health professionals, healthcare system decision-makers
and policy-makers, patients and Canadian population.
We will reach out to these target audiences through
linkage and exchange activities, including presentation
of study results at local, national and international scien-
tific meetings attended by interested stakeholders in the
obesity, reproductive endocrinology, fertility and health
services fields and publication in scientific journals, but
also by direct reports to healthcare system decision-
makers. A clear summary of research results, including
key messages targeted for each selected audience and
synthesized results, will be available (printed and on a
web site). Local and national media will be invited to
press conferences and we will schedule private meetings
with important decision-makers to whom our findings
are relevant.
Discussion
This paper has outlined the protocol of a study assessing
clinical outcomes and costs of a transferable interdiscip-
linary lifestyle intervention, before and during preg-
nancy, in obese infertile women. We are using a RCT
design for proximal clinical outcomes, and mixed design
for cost-effectiveness evaluation and qualitative assess-
ment for the purpose of future dissemination and know-
ledge transfer. To our knowledge, we are the first in the
world to conduct such a program with lifestyle interven-
tion continuing throughout fertility treatments and preg-
nancy. This project is very important as it will generate
Duval et al. BMC Obesity  (2015) 2:47 Page 12 of 15
new knowledge about the implementation, impacts and
costs of a lifestyle management program in obese infer-
tile women. The results of this study will provide valu-
able information on feasibility and transferability of such
a program, including identification of barriers and solu-
tions. We expect that our program will improve the life-
style and fertility of the participants and reduce maternal
and fetal complications during pregnancy, as compared
with our different control groups. A significant reduc-
tion in cost per live birth and cost-effectiveness ratio is
also anticipated.
Although this research protocol is innovative and uses
a robust methodology, some limitations need to be ac-
knowledged. First, implementation and outcome evalu-
ation of the lifestyle program will take place in a single
clinic. However, a RCT at the CHUS will be performed
with sufficient power to assess the primary outcome. Re-
sults will also be compared to three other clinics, which
is an ideal first step for the future development of a mul-
ticenter RCT. It is important to appropriately design and
evaluate the program in one center before transferring it
to other centers. Second, some of the outcome measures
will be self-reported and might be biased. However, such
bias should be similar in both randomized groups and
the results will be triangulated with data from many dif-
ferent sources (administrative data, questionnaires, focus
groups, etc.). Third, most of the outcomes will be
assessed only retrospectively in the clinics of compari-
son. This might introduce an evaluation bias although
multiple sources of information will be used and com-
pared. A recall bias is also possible for the evaluation of
costs for the patients’ viewpoint in these clinics, but the
same estimations will be performed in Sherbrooke and
compared with real costs, which will allow the determin-
ation of the degree of this bias for comparison clinics.
Fourth, in Sherbrooke, fertility treatments, including
IVF, will be covered by the public health care system.
Therefore, some results may not reflect all North Ameri-
can fertility clinics, but the same results will be com-
pared to clinics in other provinces where fertility
treatments are not covered.
The outcome measures of this study will be relevant
to a number of health systems’ managers and policy-
makers. Indeed, new approaches aiming at increasing ef-
ficiency and reducing costs of fertility treatments, while
improving care, are thus very pertinent for these policy-
makers. This research proposal is completely in line with
those objectives and is developed in partnership with
local, provincial and national decision-makers, which in-
creases the potential impact and use of the findings.
Generalizability of our findings is increased by the evalu-
ation of clinics from three different provinces and the in-
volvement of the CON as a partner. Furthermore,
experts and decision-makers from various provinces will
participate on the Advisory committee to ensure that
the developed intervention can be applied in other con-
texts. Early and active involvement of decision-makers
will ensure that the intervention is appropriately de-
signed to be implemented in most North American fer-
tility clinics.
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